Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The MOU will involve product collaboration from both companies with a goal of propelling PFAS destruction in groundwater globally
The investment will enable the company to enter European markets as well as enhance margins in current markets
Sanjeev is currently the Country President for AstraZeneca Malaysia
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
EC grants conditional marketing authorization based on the EFFISAYIL trial
Since inception, more than 3.6 crore pregnant women have received comprehensive ANC under this programme across all states and UTs
Subscribe To Our Newsletter & Stay Updated
